Clinical Trial: NCT05163249
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Status:
UNKNOWNPhase:
Phase 2| Lead Sponsor: | Guangdong Association of Clinical Trials |
| Information Provided By: | Guangdong Association of Clinical Trials |
| Last Update Posted: | 2024-02-09 |
Study Overview
Brief Summary
This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitinib as first-line therapy in patients with de novo MET positive, EGFR-mutant advanced NSCLC.
Official Title
A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Osimertinib
- Drug: Savolitinib
Other Study ID Numbers
- CTONG 2008
Start Date (Actual)
2022-05-31
Primary Completion Date (Estimated)
2024-04
Study Completion Date (Estimated)
2026-08
Enrollment (Estimated)
44
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Guangdong Association of Clinical Trials |
| Information Provided By: | Guangdong Association of Clinical Trials |
| Last Update Posted: | 2024-02-09 |
Study Overview
Brief Summary
This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitinib as first-line therapy in patients with de novo MET positive, EGFR-mutant advanced NSCLC.
Official Title
A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Osimertinib
- Drug: Savolitinib
Other Study ID Numbers
- CTONG 2008
Start Date (Actual)
2022-05-31
Primary Completion Date (Estimated)
2024-04
Study Completion Date (Estimated)
2026-08
Enrollment (Estimated)
44
Study Type
Interventional
Phase
Phase 2